Article info
Clinical and epidemiological research
Extended report
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
- Correspondence to Dr Wietske Kievit, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands; wietske.kievit{at}radboudumc.nl
Citation
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study
Publication history
- Received July 27, 2015
- Revised December 7, 2015
- Accepted December 20, 2015
- First published January 13, 2016.
Online issue publication
October 11, 2016
Article Versions
- Previous version (13 January 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/